Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ENTA
Strong SellEnanta Pharmaceuticals, Inc. · Healthcare · United States · $396M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs for viral infections and liver diseases. The company utilizes proprietary chemistry platforms and strong R&D capabilities, leading to partnerships with major pharmaceutical companies for drug development and commercialization. Enanta is a specialized biotech firm known for its expertise in infectious diseases, particularly Hepatitis C and respiratory syncytial virus (RSV).
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.2M | 79.2M | 67.6M | 65.3M | -8.8% | 65.3M | 63.5M | 65.2M | -0.1% |
| EPS | -5.91 | -6.38 | -5.48 | -3.84 | — | -2.42 | -2.36 | -2.33 | — |
| Shares | 20.8M | 21.1M | 21.2M | 21.4M | +2.9% | — | — | — | — |
| Debt | 25.3M | 26.5M | 55.5M | 57.9M | 31.8% | 182.0M | — | — | — |
| Equity | 321.3M | 216.7M | 128.8M | 64.7M | -41.4% | — | — | — | — |
| Op CF | -84.8M | -103.2M | -78.8M | -19.3M | — | -35.3M | — | — | — |
| Inv CF | 54.9M | -53.6M | 58.2M | 40.3M | — | — | — | — | — |
| Fin CF | 20.0M | 198.1M | -27.6M | -26.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ENTA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ENTA | Enanta Pharmaceuticals, Inc.(you) | $396M | 16 | Strong Sell |
| LRMR | Larimar Therapeutics, Inc. | $417M | 18 | Strong Sell |
| FHTX | Foghorn Therapeutics Inc. | $356M | 16 | Strong Sell |
| DMAC | DiaMedica Therapeutics Inc. | $345M | 17 | Strong Sell |
| GALT | Galectin Therapeutics Inc. | $405M | 13 | Strong Sell |
| RCKT | Rocket Pharmaceuticals, Inc. | $424M | 13 | Strong Sell |
| STRO | Sutro Biopharma, Inc. | $339M | 15 | Strong Sell |
| IRD | Opus Genetics, Inc. | $307M | 15 | Strong Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $312M | 18 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 17 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%